Having trouble accessing articles? Reset your cache.

BL-7040: Phase IIa data

BioLineRx reported data from an open-label, Israeli Phase IIa trial in 16 evaluable patients with moderately active UC showing that oral BL-7040 for 5 weeks met the primary endpoint of achieving a clinical response. Specifically,

Read the full 351 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE